Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry

514 views

Published on

  • Be the first to comment

  • Be the first to like this

2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry

  1. 1. 2012 Deep Research Report on Global and China SynthesisPolypeptide Drug IndustryReport Details:Published:September 2012No. of Pages: 305Price: Single User License – US$24002012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry wasprofessional and depth research report on China Synthesis Polypeptide Drug industry. The reportfirstly introduced Synthesis Polypeptide Drug basic information included Synthesis PolypeptideDrug definition classification application industry chain structure industry overview; internationalmarket analysis, China domestic market analysis, Macroeconomic environment and economicsituation analysis and influence, Synthesis Polypeptide Drug industry policy and plan, SynthesisPolypeptide Drug product specification, manufacturing process, product cost structure etc. thenstatistics China key manufacturers Synthesis Polypeptide Drug capacity production cost priceprofit production value gross margin etc details information, at the same time, statistics thesemanufacturers Synthesis Polypeptide Drug products customers application capacity marketposition company contact information etc company related information, then collect all thesemanufacturers data and listed China Synthesis Polypeptide Drug capacity production capacitymarket share production market share supply demand shortage import export consumption etcdata statistics, and then introduced China Synthesis Polypeptide Drug 2009-2013 capacityproduction price cost profit production value gross margin etc information. And also listedSynthesis Polypeptide Drug upstream raw materials equipments and Sharp Solarnstream clientsalternative products survey analysis and Synthesis Polypeptide Drug marketing channels industrydevelopment trend and proposals. In the end, this report introduced Synthesis Polypeptide Drugnew project SWOT analysis Investment feasibility analysis investment return analysis and alsogive related research conclusions and development trend analysis of China Synthesis PolypeptideDrug industry. In a word, it was a depth research report on China Synthesis Polypeptide Drugindustry. And thanks to the support and assistance from Synthesis Polypeptide Drug industrychain related technical experts and marketing engineers during Research Team survey andinterviews.Get your copy of this report @http://www.reportsnreports.com/reports/190930-2012-deep-research-report-on-global-and-china-synthesis-polypeptide-drug-industry.html
  2. 2. Major points covered in Table of Contents of this report includeTable of ContentsChapter One Synthesis Polypeptide Drug Industry Overview 11.1 Synthesis Polypeptide Drug Definition 11.2 Synthesis Polypeptide Drug Classification and Application 31.3 Professional Terms Interpretation 81.4 Synthesis Polypeptide Drug Industry Chain Structure 121.5 Synthesis Polypeptide Drug Industry Overview 14Chapter Two Synthesis Polypeptide Drug International and China Market Analysis 162.1 Synthesis Polypeptide Drug Industry International Market Analysis 162.1.1 Synthesis Polypeptide Drug International Market Development History 162.1.2 Synthesis Polypeptide Drug Product and Technology Developments 182.1.3 Synthesis Polypeptide Drug Competitive Landscape Analysis 252.1.4 Synthesis Polypeptide Drug International Key Countries Development Status 282.1.5 Synthesis Polypeptide Drug International Market Development Trend 302.2 Synthesis Polypeptide Drug China Market Analysis 332.2.1 Synthesis Polypeptide Drug China Market Development History 332.2.2 Synthesis Polypeptide Drug Product and Technology Developments 332.2.3 Synthesis Polypeptide Drug Competitive Landscape Analysis 352.2.4 Synthesis Polypeptide Drug China Key Regions Development Status 372.2.5 Synthesis Polypeptide Drug China Market Development Trend 372.3 Synthesis Polypeptide Drug International and China Market Comparison Analysis 42Chapter Three Major Synthesis Polypeptide Drug Analysis 433.1 Immunity Regulating Medicine (Allergy Infection and Immune) 433.1.1 Glatiramer Injection (Glatiramer Acetate) 433.1.2 Thymalfasin for Injection 463.1.3 Thymopentin Injection 493.1.4 Thymopetidum Injection 533.1.5 Summary 553.2 Digestive System Drugs (Gastrointestinal Type) 573.2.1 Octreotide Acetate Injection 573.2.2 Somatostatin for Injection 613.3 Bone and Connective Tissue Types (Thyroid hormones Drug) 663.3.1 Salmon Calcitonin Injection 673.3.2 Elcatonin Injection 703.3.4 TerfparaLide Injectlon 723.4 Gynecologic or Obstetric Drug 763.4.1 Oxytocin Injection 763.4.2 Carbetocin Injection 81
  3. 3. 3.4.3 Acetate Atosiban Injection 833.5 Tumor Drug (hCG) 863.5.1 Leuprorelin Acetate Microspheres for Injection 873.5.2 Goserelin Acetate 893.5.3 Triptorelin Acetate Injection 923.5.4 Chorionic Gonadotrophin for Injection 953.6 Urinary System Drug (Diabetes Insipidus) 983.6.1 Desmopressin Acetate Injection 983.6.2 Terlipressin for Injection 1013.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents) 1053.7.1 Biosynthetic Glucagon for Injection 1053.7.2 Exenatide Injection 106Chapter Four Synthesis Polypeptide Drug Development Environmental Analysis 1094.1 Chinas Macroeconomic Environment Analysis 1094.1.1 China GDP Analysis 1094.1.2 China CPI Analysis 1114.2 European Economic Environmental Analysis and Impact 1134.3 United States Economic Environmental Analysis and Impact 1164.4 Japan Economic Environmental Analysis and Impact 1194.5 Global Economic Environmental Analysis and Impact 1204.5.1 Global Economic Environmental Analysis 1204.5.2 Global Economic Influence 121Chapter Five Synthesis Polypeptide Drug Development Policy and Plan 1215.1 China Government Policy and Development Plan 1215.2 Industry Policy and Standard 1225.3 Technical Standard 1255.4 Technology Replacement and R&D Trends 1265.5 Hotspots and Influence 127Chapter Six Synthesis Polypeptide Drug Manufacturing Process and Cost Structure 1326.1 Synthesis Polypeptide Drug Manufacturing Process Overview 1326.2 Synthesis Polypeptide Drug Manufacturing Process Analysis 1356.3 Synthesis Polypeptide Drug Cost Structure Analysis 138Chapter Seven 2009-2013 Synthesis Polypeptide Drug Productions Supply Sales DemandMarket Status and Forecast 1407.1 2009-2013 Synthesis Polypeptide Drug Capacity Production Overview 1407.1.1 2009-2013 Global and China Synthesis Polypeptide Drug Capacity Production 1407.1.2 2009-2013 Synthesis Polypeptide Drug Production Market Share 1467.1.3 2009-2013 Synthesis Polypeptide Drug Demand Overview 152
  4. 4. 7.1.4 2009-2013 Synthesis Polypeptide Drug Supply Demand and Shortage 1527.1.5 2009-2013 Synthesis Polypeptide Drug Production Import Export Consumption 1537.1.6 2009-2013 Synthesis Polypeptide Drug Cost Price Production Value Gross Margin 1547.2 Different Type Synthesis Polypeptide Drug Sales and Market Scale Analysis 1567.2.1Thymopentin Injection 1567.2.2 Thymalfasin Injection 1587.2.3 Calcitonin Injection 1597.2.4 Somatostatin for Injection 1617.2.5Octreotide Acetate Injection 1627.2.6 Desmopressin Acetate Injection 1637.3 Synthesis Polypeptide Drug Market Summary 165Chapter Eight Synthesis Polypeptide Drug Key Manufacturers 1708.1 Novartis 1708.2 Merck Serono 1768.3 Ferring Pharmaceuticals 1818.4 Ipsen PHarma Biotech 1888.5 Lilly 1918.6Asahi Kasei 1958.7 AstraZeneca 1998.8 SciClone Pharmaceuticals 2038.9 Takeda 2068.10 HYBIO Pharmaceutical Co.,Ltd (Shenzhen Stock:300199) 2108.11 Hainan Zhonghe Pharmaceutical Co.,Ltd 2158.12 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd 2198.13 Beijing Yingu Century Pharmaceutical Co.,Ltd (Beijing Shiqiao Bio-Pharmaceutical Co.,Ltd)2248.14 Hainan Shuangcheng Pharmaceuticals Co.,Ltd 2278.15 Livzon Pharmaceuticals Co.,Ltd (Livzon:000513) 2348.16 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd 2388.17 Chengdu Tiantaishan Pharmaceutical Co.,Ltd 2428.18 Beijing Shuanglu Pharmaceutical Co.,Ltd 2508.19 Yangzijiang Pharmaceutical Co.,Ltd 2578.20 Changzhou Siyao Pharmaceutical Co.,Ltd 262Chapter Nine Up and Down Stream Industry Analysis and Influence 2679.1 Upstream Raw Materials Price Analysis and Influence 2679.1 Upstream Equipments Market Analysis and Influence 2699.3 Downstream Demand Analysis and Influence 2709.4 Industry Policy Analysis and Influence 271Chapter Ten Synthesis Polypeptide Drug Marketing Channels Analysis 272
  5. 5. 10.1 Synthesis Polypeptide Drug Marketing Channels Status 27210.1.1 Drugs Marketing Channel Developemnt History 27210.1.1 Prescription Drug Marketing Development Status 27310.2 Synthesis Polypeptide Drug Marketing Channels Management 27410.3 Synthesis Polypeptide Drug Marketing Channels Establishment 27510.4 Synthesis Polypeptide Drug Marketing Channels Development Trend 276Chapter Eleven Synthesis Polypeptide Drug Industry Development Trend 27811.1 2012-2016 Synthesis Polypeptide Drug Industry Development Trend 27811.2 2012-2016 Market Potential Forecast 27911.3 2012-2016 R&D Trend 28011.3.1Polypeptide Drug Technical Development Status 28011.3.2 Polypeptide Drug and Health Care Products Research and Manufacturing Overview 28211.3.3 China Polypeptide Drug Development Direction and Prospect 28311.4 2012-2016 Marketing Channels Change Trend 28514.4.1 Prescription Drug Marketing Channels Change Trend 28514.4.2 Prescription Drug Sales Method Five Trend 28611.5 2012-2016 Competition Pattern Development Trends 288Chapter Twelve Synthesis Polypeptide Drug Industry Development Proposals 28912.1 Macroeconomic Development Countermeasures 28912.2 New Firms Enter Market Strategy 29012.2.1 New Business Entry Barriers 29012.2.2 New Corporate Strategy 29012.3 New Project Investment Proposal 29312.4 Marketing Channel Strategy Proposals 29412.5 Competitive Environment Strategy Proposals 29612.5.1 Competitive Environment Analysis 29612.5.2 Strategy Proposals 297Chapter Thirteen Synthesis Polypeptide Drug New Project Investment Feasibility Analysis 30013.1 Synthesis Polypeptide Drug Project SWOT Analysis 30013.2 Synthesis Polypeptide Drug New Project Investment Feasibility Analysis 30213.2.1 Buildings 30213.2.2 Investment 30313.2.3 Project Schedule 30313.2.4 Project Investment Return and Feasibility Analysis 304Chapter Fourteen Synthesis Polypeptide Drug Industry Research Conclusions 304List Of Tables and Figures
  6. 6. Figure Synthesis Polypeptide Process Flow 1Figure Synthesis Polypeptide Drug Picture-Thymopentin Injection 2Figure Polypeptide Applications on Health Care Food and Cosmetics Fields 4Figure Polypeptide Drug Manufacturing Process Method 4Table Synthesis Polypeptide Drug Classification and Application List 5Table Synthesis Polypeptide Drug Product Name Use and Annual Sales Revenue (USD) List 6Table Listed Polypeptide Drug Name Type Indication 6Figure Pharmaceutical Industry Value Chain Structure 12Figure Pharmaceutical Industry Industry Chain Structure 12Figure Synthesis Polypeptide Drug Industry Chain Structure 13Figure Synthesis Polypeptide Drug Industrialization System 13Figure 2000-2011 China Pharmaceutical Industry Sales Revenue and Total Profit (100 MillionRMB) and Growth Rate 14Figure 2007-2015 China Synthesis Polypeptide Drug Market Scale (100 Million RMB) and GrowthRate 15Figure DNA Transcribed into RNA Diagram 17Figure RNA Translated into Polypeptide Chains Molecular Diagram 18Table Polypeptide Drug Three Manufacturing Methods 19Figure 1984 Chemistry Nobel Prize Winner Robert Bruce Merrifield 20Figure Polypeptide Solid Phase Synthesis Principle 20Figure Solid Phase Polypeptide Synthesis 21Figure United States CS Three Channel Full Automatic Polypeptide Synthetic Instrument 22Figure Homemade CS136 Model Research Polypeptide Synthetic Instrument 23Figure Large Scale Liquid Phase Synthesis of Polypeptide 24Figure Thin Film Evaporator (for perishable goods Concentration) 24Table Global 2008 Revenue More than 1 Billion Polypeptide Drug Brands List 25Table Some Listed Polypeptide Drug Indication Classification 26Figure Listed Polypeptide Drug Indication Classification Market Share 26Figure 2004-2014 Global Pharmaceutical Sales Revenue (Billion USD) and Growth Rate 30Figure 2009-2013 International Synthesis Polypeptide Drug Market Scale (100 Million RMB) andGrowth Rate 31Table 2011 Some Polypeptide Drug Global Sales Revenue (100 Million USD) 31Figure Each Year Enter Clinical Research Polypeptide Drug Quantity (Piece) 32Table 17 Emerging Pharmaceutical Market Sizes (Billion USD) 38Figure 2007-2015 China Pharmaceutical Sales Revenue (100 Million USD) 39Figure 2009-2015 China Polypeptide Drug Market Scale (100 Million RMB) and Growth Rate 39Figure 2009-2015 China Chemical Synthesis Polypeptide Drug Market Scale (100 Million RMB)and Growth Rate 40Figure 2009-2015 China Chemical Synthesis Polypeptide Drug Market Scale (100 Million RMB)and Proportion of China Total Polypeptide Drug Market Scale 41Figure 2007-2009 China Chemical Synthesis Polypeptide Drug Types Market Share 41Table Copaxone Neuron Structure Diagram 44
  7. 7. Table Thymalfasin for Injection (Thymalfasin a1) Suppliers List 48Table 2010 Thymalfasin for Injection Key Products Price (RMB/Piece) List 49Table Some Thymopentin Injection Suppliers List 51Table Thymopentin Injection Hospital Purchase Price (RMB/Piece) List 52Table Thymopetidum Injection Thymopentin Injection Thymalfasin Injection Comparison 56Table Octreotide Acetate Injection Key Suppliers List 59Table 2012 Hebei Province Octreotide Acetate Injection Bid Price List 60Tale Somatostatin for Injection Key Suppliers List 64Table Somatostatin for Injection Key Products Hospital Average Purchae Price List 64Table 2012 Hebei Province Somatostatin for Injection Key Suppliers List 65Table Salmon Calcitonin Injection Suppliers List 69Table Salmon Calcitonin Injection/Nasal Spray Products Hospital Purchase Price List 69Table Salmon Calcitonin Injection/Nasal spray Products Retail Price List 70Table Elcatonin Injection Key Suppliers and Product Selling Price List 72Figure TerfparaLide Injectlon—Forsteo Injection Pen Parts 75Table 2011Q1 China Some Aproved New Drug Number, Specifications Suppliers and Indication76Table 2012 New Add Key Monitoring Drug Table--TerfparaLide Injectlon 76Table Oxytocin Injection Key Suppliers List 78Table Oxytocin Injection Suppliers Products Models List 80Table Carbetocin Injection Suppliers List 83Table Acetate Atosiban Injection Supplier Product Specification Price List 85Table Leuprorelin Acetate Microspheres for Injection Suppliers Product Specification Price List88Table Triptorelin Acetate Injection Suppliers Product Specification Price List 94Table Chorionic Gonadotrophin for Injection Suppliers Product Specifications List 97Table 2011 Some Hormone Drugs Independent Pricing and Uniform Pricing Comparison 98Table Desmopressin Acetate Injection Key Suppliers List 100Table Desmopressin Acetate Injection Key Suppliers Forms Product Specifications and Bid PriceList 101Table Terlipressin for Injection Key Brands Manufacturers and Retail Prices 104Table Biosynthetic Glucagon for Injection Suppliers and Retail Prices List 106Table Exenatide Suppliers Product Specifications Retail Prices List 109Figure 2007-2015 China Medical Industry Total Production Value (100 Million RMB) and GrowthRate 110Table 2006-2011 China GDP (1000 Million RMB) and Growth Rate 110Figure 2007-2011 China Medical Industry Total Value and Its Proportion of China Total GDP 111Figure 2007-2015 China Individual Medical Expenditure (RMB) 112Figure 2007-2015 China Health Expenditure Per Capita and National Medical ExpenditureComparison 112Figure 2011-2016 China Population Growth and Aging Condition 113Figure 2006-2011 Europe Several Countries PMI Trend 114
  8. 8. Figure United States CPI and PCE Growth Comparison 117Figure United States Private Savings Rate Change and Net Export /GDP Proportion ChangeTrend 118Figure United States Public Debt and Deficit Proportion of GDP 119Figure Japan GDP and CPI Growth Rate Comparison 119Figure 2009-2011 China Health Capital Investment (100 Million RMB) 122Table China Pharmaceutical Industry All major Departments and Regulatory Functions 122Table Pharmaceutical Industry main Laws and Regulations and Policies 125Table 2009-2012 China Medical and Health System Reform Important Policy 128Table 2009-2012 China Related Pharmaceutical Product Quality Supervision Policy 129Table 2008-2012 China Development and Reform Commission Policy on Drug Price ManagementPolicies 130Figure PTIPolypeptide Synthetic Instruments Picture 133Table Synthesis Polypeptide Drug Technology Processes List 133Figure Polypeptide Pharmaceutical Raw Materials Manufacturing Process Flow 135Figure Freeze Dried Powder Injection Manufacturing Process Flow 136Figure Small Capacity Injection Manufacturing Process Flow 136Figure Thymalfasin API Manufacturing Process Flow 137Figure Thymalfasin Injection Manufacturing Process Flow 138Figure International Synthesis Polypeptide Drug Cost Structure 139Table 2009-2011 China Synthesis Polypeptide Drug Cost Structure 139Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Capacity and TotalCapacity (10K Piece) List 140Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Capacity Market ShareList 140Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Production and TotalProduction (10K Piece) List 141Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Production Market ShareList 141Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Capacity and TotalCapacity (10K Piece) List 142Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Capacity Market ShareList 142Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Production and TotalProduction (10K Piece) List 143Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Production Market ShareList 143Figure 2009-2013 Global Synthesis Polypeptide Drug Capacity Production (10K Piece) andGrowth Rate 144Table 2009-2013 Global Synthesis Polypeptide Drug Capacity Utilization Rate List 144Figure 2009-2013 China Synthesis Polypeptide Drug Capacity Production (10K Piece) and GrowthRate 145
  9. 9. Table 2009-2013 China Synthesis Polypeptide Drug Capacity Utilization Rate List 145Table 2009-2013 Key Manufacturers Synthesis Polypeptide Drug China Sales (10K Piece) Top20List 146Table 2009-2013 Key Manufacturers Synthesis Polypeptide Drug China Sales Top20 MarketShare List 147Table 2010 Key Manufacturers Synthesis Polypeptide Drug China Sales Revenue (100 MillionRMB) Top10 List 147Table 2008-2010 Key Manufacturers Synthesis Polypeptide Drug China Sales Revenue Top10Market Share List 148Figure 2011 Key Manufacturers Synthesis Polypeptide Drug China Sales Market Share 149Figure 2012 Key Manufacturers Synthesis Polypeptide Drug China Sales TOP20 Market Share150Figure 2011 China Key Manufacturers Synthesis Polypeptide Drug Production Market Share 151Figure 2012 China Key Manufacturers Synthesis Polypeptide Drug Production Market Share 151Table 2009-2013 Global Synthesis Polypeptide Drug Demand (10K Piece) and Growth Rate 152Table 2009-2013 China Synthesis Polypeptide Drug Demand (10K Piece) and Growth Rate 152Table 2009-2013 China Synthesis Polypeptide Drug Supply Demand and Shortage (10K Piece)153Table 2009-2013 Nine Foreign Enterprises Synthesis Polypeptide Drug China Sales (10K Piece)List 153Table 2009-2013 China Synthesis Polypeptide Drug Production Import Export Consumption (10KPiece) List 154Table 2007-2009 China Synthesis Polypeptide Drug Price (RMB/Piece) Distribution 154Table 2009-2011 Hainan Shuangcheng Pharmaceuticals Some Synthesis Polypeptide Drug PriceCost (RMB/Piece) Gross Margin List 155Table 2009-2013 China Synthesis Polypeptide DrugProduction (10K Piece) Price Cost Gross(RMB/Piece) Production Value (10K RMB) Gross Margin List 155Figure 2011 China Synthesis Polypeptide Drug Market Share by Different Type Drug 156Figure 2008-2014 China Thymopentin Injection Market Scale (100 Million RMB) and GrowthRate 157Figure 2008-2014 China Thymopentin Injection Sales (10K Piece) and Growth Rate 157Figure 2008-2014 China Thymalfasin Injection Market Scale (100 Million RMB) and Growth Rate158Figure 2008-2014 China Thymalfasin Injection Sales (10K Piece) and Growth Rate 159Figure 2008-2014 China Calcitonin Injection Market Scale (100 Million RMB) and Growth Rate160Figure 2008-2014 China Calcitonin Injection Sales (10K Piece) and Growth Rate 160Figure 2008-2014 China Somatostatin for Injection Market Scale (100 Million RMB) and GrowthRate 161Figure 2008-2014 China Somatostatin for Injection Sales (10K Piece) and Growth Rate 162Figure 2008-2014 China Octreotide Acetate Injection Market Scale (100 Million RMB) and GrowthRate 163
  10. 10. Figure 2008-2014 China Octreotide Acetate Injection Sales (10K Piece) and Growth Rate 163Figure 2008-2014 China Desmopressin Acetate Injection Market Scale (100 Million RMB) andGrowth Rate 164Figure 2008-2014 China Desmopressin Acetate Injection Sales (10K Piece) and Growth Rate164Table 2009-2011 China Chemical Synthesis Polypeptide Drug Injection Distribution List 165Figure 2010 Global Polypeptide Drug Market Structure by Treatment Class 165Table Research or Listed Polypeptide Drugs List 166Figure 1990-2010 China Resident Three Types of Chronic Disease Prevalence (1/100K) ChangeTrend 167Figure 2010 China Synthesis Polypeptide Drug Hospital Terminal Sales Market ShareDistribution 168Figure 2010 China Synthesis Polypeptide Drug Top10 Manufacturers Sales Revenue (100 MillionRMB) 168Figure China Synthesis Polypeptide Drug Prices Distribution 169Figure Use Me-Too Model Developed Polypeptide Drug List 169Table Novartis Company Information Table (Products Applications Manufacturing Base LocationCapacity Expansion Plan Market Position Contact Information etc 13 Items) 170Figure Novartis China Market Sales Synthesis Polypeptide Drug--Octreotide Acetate Injection173Figure Novartis China Market Sales Synthesis Polypeptide Drug--Somatostatin Acetate forInjection 173Figure Novartis China Market Sales Synthesis Polypeptide Drug--salmon Calcitonin Nasal Spray174Table 2009-2013 Novartis Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross(RMB/Piece) Production Value (10K RMB) Gross Margin List 174Figure 2009-2013 Novartis Synthesis Polypeptide Drug Capacity Production (10K Piece) andGrowth Rate 175Table Merck Serono Company Information Table (Products Applications Manufacturing BaseLocation Capacity Expansion Plan Market Position Contact Information etc 13 Items) 176Figure Merck Serono Synthesis Polypeptide Drug--Recombinant Human Follitropin Alfa Solutionfor Injection 178Figure Merck Serono Synthesis Polypeptide Drug--Somatostatin for Injection 179Figure Merck Serono Synthesis Polypeptide Drug--Gonadorelin for Injection 179Table 2009-2013 Merck Serono Synthesis Polypeptide Drug Production (10K Piece) Cost PriceGross (RMB/Piece) Production Value (10K RMB) Gross Margin List 180Figure 2009-2013 Merck Serono Synthesis Polypeptide Drug Capacity Production (10K Piece)and Growth Rate 181Table Ferring Pharmaceuticals Company Information Table (Products Applications ManufacturingBase Location Capacity Expansion Plan Market Position Contact Information etc 13 Items) 182Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Minirin 183Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Decapeptyl
  11. 11. 184Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Pentasa 184Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Glypressin185Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Octostim 186Table 2009-2013 Ferring Pharmaceuticals Synthesis Polypeptide Drug Production (10K Piece)Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 186Figure 2009-2013 Ferring Pharmaceuticals Synthesis Polypeptide Drug Capacity Production (10KPiece) and Growth Rate 188Table Ipsen PHarma Biotech Company Information Table (Products Applications ManufacturingBase Location Capacity Expansion Plan Market Position Contact Information etc 13 Items) 188Figure Ipsen PHarma Biotech Synthesis Polypeptide Drug--Triptorelin Acetate for Injection 190Table 2009-2013 Ipsen PHarma Biotech Synthesis Polypeptide Drug Production (10K Piece) CostPrice Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 190Figure 2009-2013 Ipsen PHarma Biotech Synthesis Polypeptide Drug Capacity Production (10KPiece) and Growth Rate 191Table Lilly Company Information Table (Products Applications Manufacturing Base LocationCapacity Expansion Plan Market Position Contact Information etc 13 Items) 192Figure Lilly Some China Listed Synthesis Polypeptide Drug List 194Table 2009-2013 Lilly Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross(RMB/Piece) Production Value (10K RMB) Gross Margin List 194Figure 2009-2013 Lilly Synthesis Polypeptide Drug Capacity Production (10K Piece) and GrowthRate 195Table Asahi Kasei Company Information Table (Products Applications Manufacturing BaseLocation Capacity Expansion Plan Market Position Contact Information etc 13 Items) 195Figure Asahi Kasei Synthesis Polypeptide Drug--Elcatonin Injection 198Table 2009-2013 Asahi Kasei Synthesis Polypeptide Drug Production (10K Piece) Cost PriceGross (RMB/Piece) Production Value (10K RMB) Gross Margin List 198Figure 2009-2013 Asahi Kasei Synthesis Polypeptide Drug Capacity Production (10K Piece) andGrowth Rate 199Table AstraZeneca Company Information Table (Products Applications Manufacturing BaseLocation Capacity Expansion Plan Market Position Contact Information etc 13 Items) 199Figure AstraZeneca China Selling Synthesis Polypeptide Drug—Goserelin Acetate Slow ReleaseImplantation Agent 201Table 2009-2013 Jiangsu AstraZeneca Synthesis Polypeptide Drug Production (10K Piece) CostPrice Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 202Figure 2009-2013 Jiangsu AstraZeneca Synthesis Polypeptide Drug Capacity Production (10KPiece) and Growth Rate 203Table SciClone Pharmaceuticals Company Information Table (Products ApplicationsManufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13Items) 204Figure SciClone Pharmaceuticals Synthesis Polypeptide Drug-- Thymopetidum Injection 205
  12. 12. Table 2009-2013 SciClone Pharmaceuticals Synthesis Polypeptide Drug Production (10K Piece)Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 205Figure 2009-2013 SciClone Pharmaceuticals Synthesis Polypeptide Drug Capacity Production(10K Piece) and Growth Rate 206Table Takeda Company Information Table (Products Applications Manufacturing Base LocationCapacity Expansion Plan Market Position Contact Information etc 13 Items) 206Figure Takeda--Leuprorelin Acetate Microspheres for Injection 208Table 2009-2013 Takeda Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross(RMB/Piece) Production Value (10K RMB) Gross Margin List 209Figure 2009-2013 Takeda Synthesis Polypeptide Drug Capacity Production (10K Piece) andGrowth Rate 209Table HYBIO Pharmaceutical Co.,Ltd Company Information Table (Products ApplicationsManufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13Items) 210Figure 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug 211Table 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10KPiece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 213Figure 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug CapacityProduction (10K Piece) and Growth Rate 215Table Hainan Zhonghe Pharmaceutical Co.,Ltd Company Information Table (ProductsApplications Manufacturing Base Location Capacity Expansion Plan Market Position ContactInformation etc 13 Items) 216Figure Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug 217Table 2009-2013 Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production(10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 217Figure 2009-2013 Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug CapacityProduction (10K Piece) and Growth Rate 219Table Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Company Information Table(Products Applications Manufacturing Base Location Capacity Expansion Plan Market PositionContact Information etc 13 Items) 219Figure Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis PolypeptideDrug—Thymalfasin Injection 221Figure Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis PolypeptideDrug—Thymopentin Injection 222Table 2009-2013 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis PolypeptideDrug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) GrossMargin List 222Figure 2009-2013 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis PolypeptideDrug Capacity Production (10K Piece) and Growth Rate 223Table Beijing Yingu Century Pharmaceutical Co.,Ltd Company Information Table (ProductsApplications Manufacturing Base Location Capacity Expansion Plan Market Position ContactInformation etc 13 Items) 224
  13. 13. Figure Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-SalmonCalcitonin Nasal Spray 225Figure Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-ThymopentinInjection 226Table 2009-2013 Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide DrugProduction (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross MarginList 226Figure 2009-2013 Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide DrugCapacity Production (10K Piece) and Growth Rate 227Table Hainan Shuangcheng Pharmaceuticals Co.,Ltd Company Information Table (ProductsApplications Manufacturing Base Location Capacity Expansion Plan Market Position ContactInformation etc 13 Items) 228Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug--ThymalfasinInjection 229Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug—Somatostatinfor Injection 231Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug—ThymopentinInjection 232Table 2009-2013 Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide DrugProduction (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross MarginList 233Figure 2009-2013 Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide DrugCapacity Production (10K Piece) and Growth Rate 234Table Livzon Pharmaceuticals Co.,Ltd Company Information Table (Products ApplicationsManufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13Items) 234Figure Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug 236Table 2009-2013 Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Production (10KPiece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 236Figure 2009-2013 Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug CapacityProduction (10K Piece) and Growth Rate 238Table Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Company Information Table(Products Applications Manufacturing Base Location Capacity Expansion Plan Market PositionContact Information etc 13 Items) 239Figure Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug--Thymopentin Injection 240Figure Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug--Somatostatin for Injection 240Table 2009-2013 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis PolypeptideDrug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) GrossMargin List 241Figure 2009-2013 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide
  14. 14. Drug Capacity Production (10K Piece) and Growth Rate 242Table Chengdu Tiantaishan Pharmaceutical Co.,Ltd Company Information Table (ProductsApplications Manufacturing Base Location Capacity Expansion Plan Market Position ContactInformation etc 13 Items) 242Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug—Somatostatinfor Injection 244Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug—ThymopentinInjection 246Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug—OctreotideAcetate Injection 247Table 2009-2013 Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide DrugProduction (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross MarginList 248Figure 2009-2013 Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide DrugCapacity Production (10K Piece) and Growth Rate 249Table Beijing Shuanglu Pharmaceutical Co.,Ltd Company Information Table (ProductsApplications Manufacturing Base Location Capacity Expansion Plan Market Position ContactInformation etc 13 Items) 250Figure Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-ThymopentinInjection 251Figure Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Salmon CalcitoninInjection 252Table Beijing Shuanglu Pharmaceutical Co.,Ltd Thymopentin Injection Price List 253Table 2009-2013 Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide DrugProduction (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross MarginList 256Figure 2009-2013 Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug CapacityProduction (10K Piece) and Growth Rate 257Table Yangzijiang Pharmaceutical Co.,Ltd Company Information Table (Products ApplicationsManufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13Items) 257Figure Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Somatostatin forInjection 259Figure Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection260Table 2009-2013 Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production(10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List 260Figure 2009-2013 Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug CapacityProduction (10K Piece) and Growth Rate 261Table Changzhou Siyao Pharmaceutical Co.,Ltd Company Information Table (ProductsApplications Manufacturing Base Location Capacity Expansion Plan Market Position ContactInformation etc 13 Items) 262
  15. 15. Figure Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug List 264Table Changzhou Siyao Pharmaceutical Co.,Ltd Chemical Pharmaceutical Raw Materials List264Table Changzhou Siyao Pharmaceutical Co.,Ltd Chemical Raw Materials Intermediates List 265Table 2009-2013 Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide DrugProduction (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross MarginList 266Figure 2009-2013 Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug CapacityProduction (10K Piece) and Growth Rate 266Table Synthesis Polypeptide Drug Project Key Equipments and Price (10K RMB) 269Table Synthesis Polypeptide Drug Project Equipments List and Price (10K RMB) 270Table Drugs Manufacturing Enterprise Specialized Academic Promotion Organization Frame276Figure Synthesis Polypeptide Drug Industry Entry Barriers List 293Table 2012 China Synthesis Polypeptide Drug New Project SWOT Analysis 300Table 2012 China Synthesis Polypeptide Drug New Project Buildings List 302Table 2012 China Synthesis Polypeptide Drug New Project Investments (10K RMB) List 303Table Synthesis Polypeptide Drug New Project Investment Return and Feasibility Analysis 304Contact: sales@reportsandreports.com for more information.

×